Nanorobots for the treatment of breast cancer: Exploration and advancement

Nanorobots provide a breakthrough in breast cancer treatment, using nanotechnology to identify, target, and treat tumors with unheard-of accuracy. Designed to navigate challenging biological parameters, these tiny devices deliver therapeutic medications directly to tumor sites, thereby reducing systemic toxicity and adverse effects. Nanorobots present a viable substitute for traditional treatments by including cutting-edge technologies such as targeted delivery, biocompatibility, and multifunctionality. This study aims to explore the potential of nanorobots in the treatment of breast cancer. Nanorobots offer precision-based options for breast cancer care by delivering drugs, targeting tumors, and performing diagnostic tests. For instance, DNA nanorobots are designed to recognize signals unique to a tumor and release thrombin or chemotherapy to cut off the blood supply of the tumor. Nanorobots with magnetic and enzyme propulsion improve mobility and can effectively enter tumor microenvironments. Natural homing processes are used in bio-hybrid models, which are generated from live cells, to enhance tumor targeting. Biocompatibility, operational stability, and manufacturing scalability are still issues despite these developments. Even while current propulsion technologies are inventive, they frequently have trouble navigating biological settings that are viscous. Refinement of materials, propulsion methods, and targeting tactics are necessary to overcome these obstacles and improve clinical application in the future. Nanorobots can transform the treatment of breast cancer by providing personalized, effective, and minimally invasive therapeutic alternatives. To fully realize their potential in clinical applications, current biocompatibility and technological issues must be resolved.